Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
4 clinical trials · Condition
◉ Watch Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
| Record | Firm | Date |
|---|---|---|
| Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma (NCT05202782) | Northwestern University | 2022-03-21 |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (NCT05025800) | M.D. Anderson Cancer Center | 2021-10-13 |
| Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy (NCT04870853) | M.D. Anderson Cancer Center | 2020-04-02 |
Track Refractory Aggressive B-Cell Non-Hodgkin Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.